Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis-Reference-Cited by-同舟云学术

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis

Published:2021-11-01 Issue:11 Volume:6 Page:1329
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Lehmann Lorenz H.¹²³,Cautela Jennifer⁴⁵⁶,Palaskas Nicolas⁷,Baik Alan H.⁸,Meijers Wouter C.⁹,Allenbach Yves¹⁰¹¹,Alexandre Joachim¹²,Rassaf Tienush¹³,Müller Oliver J.¹⁴¹⁵,Aras Mandar⁸,Asnani Aarti H.¹⁶,Deswal Anita⁷,Laufer-Perl Michal¹⁷,Thuny Franck⁴⁵,Kerneis Mathieu¹⁸,Hayek Salim S.¹⁹,Ederhy Stéphane²⁰,Salem Joe-Elie⁹²¹,Moslehi Javid J.⁹

Affiliation:

1. Department of Cardiology, Angiology, and Pneumology, Cardio-Oncology Unit, Heidelberg University Hospital, Heidelberg, Germany

2. German Centre for Cardiovascular Research, partner site Heidelberg/Mannheim, Heidelberg, Germany

3. German Cancer Research Centre, Heidelberg, Germany

4. Aix-Marseille University, University Mediterranean Center of Cardio-Oncology, Unit of Heart Failure and Valvular Heart Diseases, Center for Cardiovascular and Nutrition Research, Nord Hospital, Assistance Publique-Hôpitaux de Marseille, France

5. Groupe Méditerranéen de Cardio-Oncologie, Marseille, France

6. Oncosafety Network of the Early Phases Cancer Trials Center, Marseille, France

7. Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston

8. Department of Medicine, Division of Cardiology, University of California, San Francisco

9. Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

10. Department of Internal Medicine and Clinical Immunology, Sorbonne Université, Pitié-Salpêtrière University Hospital, Paris, France

11. Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France

12. Department of Pharmacology, Normandie University, University of Caen Normandy, PICARO Cardio-oncology Program, Signalisation, Électrophysiologie et Imagerie des Lésions d'Ischémie-Reperfusion Myocardique, Caen, France

13. Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

14. Department of Internal Medicine III, University of Kiel, Kiel, Germany

15. German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lübeck, Kiel, Germany

16. CardioVascular Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

17. Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

18. Sorbonne Université, ACTION Study Group, Institut National de la Santé et de la Recherche Médicale, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris, France

19. Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor

20. Hôpitaux Universitaires Paris-Est, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, Service de Cardiologie, Unico, Unité de Cardio-Oncologie, Groupe de Recherche Clinique en Cardio-Oncologie, Université Pierre et Marie Curie, Paris, France

21. Department of Pharmacology, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, UNICO-GRECO Cardio-Oncology Program, Pitié-Salpêtrière Hospital, Paris, France

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2781842/jamacardiology_lehmann_2021_rv_210002_1635348665.59463.pdf

Reference71 articles.

1. Immuno-oncology drug development goes global.;Xin Yu;Nat Rev Drug Discov,2019

2. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors.;Centanni;Clin Pharmacokinet,2019

3. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.;Yang;Eur J Cancer,2020

4. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.;Song;Leukemia,2020

5. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study.;Mo;Br J Cancer,2018

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events;Frontiers in Immunology;2024-02-05

2. Echocardiographic parameters of cardiac structure and function in the diagnosis of acute myocarditis in adult patients: A systematic review and meta‐analysis;Echocardiography;2024-02

3. THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY;2024-01-24

4. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors;Cardio-Oncology;2024-01-11

5. Protective effect of low‐intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4+ T-cell differentiation;Cancer Immunology, Immunotherapy;2024-01